Skip to main content
. 2017 Nov;363(2):136–147. doi: 10.1124/jpet.117.243477

Fig. 2.

Fig. 2.

Evaluation of in vivo efficacy of ponatinib (30 mg/kg/day) in GBM6 xenografts. (A) Kaplan-Meier curves for GBM6 flank xenografts (N = 9–10) with the endpoint of tumor size exceeding 1,500 mm3 (*P < 0.05). (B) Kaplan-Meier curves for GBM6 intracranial xenografts (N = 8–10) showing no difference in survival between placebo and ponatinib groups (P > 0.05; N.S., not significant).